Strumento inattivo

Azioni Idenix Pharmaceuticals Inc

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

AbbVie : Merck says hepatitis C drugs to lose breakthrough status	04/02/15
Idenix Pharmaceuticals : Merck dépasse les attentes malgré la concurrence des génériques	29/07/14
Apple : Wall St. edges up, lifted by mergers, acquisitions	10/06/14
Idenix Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Idenix Pharmaceuticals Inc.	10/06/14
Apple : U.S. futures dip, S&P 500 comes off fourth straight record	10/06/14

Dirigenti	Titolo	Età	Da
Teresa Dahlman IRC	Investor Relations Contact	-	-
Michele Liuzzi PRN	Corporate Officer/Principal	-	-
Adel Moussa PRN	Corporate Officer/Principal	-	01/03/02

Settore

	Variaz. 1 gen.	Capi.
CSL LIMITED	-4,66%	86,13 Mrd
SAMSUNG BIOLOGICS CO.,LTD.	+1,32%	39,82 Mrd
BIOGEN INC.	-19,27%	30,42 Mrd
UCB	+57,86%	25,23 Mrd
BIOMARIN PHARMACEUTICAL INC.	-16,09%	15,35 Mrd
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9,14%	11,95 Mrd
INCYTE CORPORATION	-17,69%	11,6 Mrd
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43,00%	11,51 Mrd
SWEDISH ORPHAN BIOVITRUM AB	+5,24%	8,71 Mrd